We were one of the three sites that accrued patients to this trial, and the benefits are compelling (a tripling of PFS, along with an OS benefit). Randomized phase II trials are usually not meant to be definitive, but these results are very informative for clinical practice. It's also important to ...

Leaving my original answer below, so I can build on it.Dr. Palma and Dr. Gomez should be congratulated by the amazing work they presented at ASTRO. These were carefully designed studies that give us extraordinary information about the potential benefit of consolidative local therapy for NSCLC. The r...

This is obviously an excellent discussion. I would concur with what has been already said. I think there are certainly some unanswered questions regarding patient selection, which lesions to consolidate, and how many lesion to offer LCT via SBRT, etc.  An important point that has been alluded t...

University of Colorado was another site that participated in this study.  I am sorry that we weren't able to accrue more patients.  One reason that it may have been difficult is that we have treated many patients with oligometastatic disease with LCT (usually an SBRT-type regimen), and the...

Thanks for your efforts gathering these high quality prospective data for us to learn from. This study is definitely going to help our patients. A question comes to mind. Might it not be deduced that prolongation of PFS helps delay (or at times even avoid) chemotherapy, cost, and toxicity? For stag...